Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Anavex (GOLD STANDARD OF CARE)
Sounds good !!!
I know some won't open this link but, this is exactly what TGD did step by step. This explains why some people are confused about dropouts and Super responder and everything that everyone is worried about Anavex not achieving.
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2254403/
Sounds like a pro!!
Have any one looked through Ariana web page? It may have some answers to the drop out rates and who did well in the low/med and high doses in the 2a trial.
Near the end of the page it's a PDF open it for presentations 1
https://www.arianapharma.com/alzheimers-disease-dementia-early-detection-and-precision-medicine-using-kem-artificial-intelligence-ai-latest-research-results-presented-by-ariana-at-the-aaic-2019/
Prior to the completion of the larger Phase 2b/3 study ANAVEX®2-73-AD-004 (NCT03790709) for the treatment of Early Alzheimer’s Disease, using precision medicine included SIGMAR1 biomarker of response,
We've already ran the precision medicine trial, now we wait. Either we good or great!
George, if you can tell us we will have 80 or so super responders! Why can't you tell us the percentage of the remaining n#s over placebo?
We can also expect that approximately 289 of the 340 participants taking Blarcamesine will do better than those on placebo.
Thank you!!
https://www.ncbi.nlm.nih.gov/books/NBK1384/
This is what I was referring to
Is it your understanding that 2-73 can be used in pregnancy to correct chromosome X to prevent rare diseases like Fragile X syndrome and others that occur?
This might contribute to the conversation
https://mailchi.mp/shakeitup/nov-research-forum-2654788?e=5cbacb683e
Sorry for your loss
Prayers for you and your family.
Wow this is great and this is most likely the delay. We're designing and building clinical trials that will soon be a platform.!
This is pure speculation, but when Missling says data is literally around the corner is it a potential partner in downtown N.Y.C?
Just makes you wonder?
NICE!!!
Our paper has been published in Current Neuropharmacology. Harald Hampel et al. (2021) Biomarker-guided pathway-based therapy in Neurology/Psychiatry. #Neurology #AlzheimersDisease https://t.co/YxuKcZIyZg
— Harald Hampel, MD, PhD (@harald_hampel) December 11, 2021
But if we can treat one we can treat them all!!!
This maybe the reason that we are waiting on our undisclosed rare disease. It's not that simple
https://fragilex.org/understanding-fragile-x/fxs-symptoms-vs-causes/?utm_campaign=Education&utm_medium=email&_hsenc=p2ANqtz-8_SBIHrYICHIDnHVFogW-4nSF_NDJpoch4y3-2KvZUSBBayxrZmHqhCSSC6yiKmOVMhjyjwu8paWbkmHZMuHRMKIBLdw&_hsmi=192871669&utm_content=192871669&utm_source=hs_email&hsCtaTracking=9ad465cd-1716-4c27-8e37-b81f9b586e16%7C8201f24c-3253-48da-bf5a-adcfc7967118
So ALS is a nothing burger?
FDA may ask for a second PIII to
satisfy the requirements of two PIII for large CNS indications.
I think that's the delay with data, is that the PDD OLE and Rett's data is good and ready for PIII
I say we start PIII for all said indication before end of year, wait for AZ read out to confirm all trials pushing them into PH IV except for Rett which will get approved by May-June IMO.
Prayers!!!
And the delay was to get it right the first time for AA in pediatrics!! Learn from the adult data BTD (changes in fda end points)implemente it into pediatric for AA!!
Wow great news!!
Yeah but what about the clinical evidence we have ?peer review papers should be adding value to the platform that's being built.
They all would rather see you die than cured..
So sad but ture.
Agree, not right. Something fishy but we know the treatment is safe and effective. Lots of families start to get their lives back.
Amen!! God bless these families
Let me guess it's already baked in the price?
What a shame, no interest in pre market. Things has to change soon real soon!! Fingers crossed ??
Hard to say what her motive is/was maybe.
Maybe her time is up/ we need a full time financial officer with a lot more skills?
This will be the
Unknown indication (FXTAS)
Carriers, FXTAS, and POI
Carriers have a small mutation in FMR1 (a premutation). Carriers do not show symptoms of Fragile X syndrome, but they may be at risk for related disorders such as Fragile X-associated Tremor/Ataxia Syndrome (FXTAS). Women who carry Fragile X may be at risk for Primary Ovarian Insufficiency which causes early menopause.
The Centers for Disease Control (CDC) published a study in 2012 which pegs the prevalence of carriers at:
1 in 151 females, or about 1 million women in the United States.
1 in 468 males, or about 320,000 men in the United States.
Why don't you sell most of your shares and they will stop!! ;)
I wouldn't be surprised if this was the reason we never received all trial data from the OLE, or from conferences.Missiling had a plan and execution is on point. Get ready for the whole set of data come this PDD results. We reset everything no question asked.
Homeostasis the whole body, this been said from day one. TIP OF THE ICEBERG OR GLACIER pick one.
Controlled short covering Going on in pre market!! $35 by Wednesday I hope.
MM holding it down for shorts to cover, that's all.
Our team is dedicated to provide for this urgent unmet need of patients with Rett syndrome, and we believe our ANAVEX®2-73 Rett syndrome program sets us on a course to potentially offer a new, unique and mechanistically differentiated treatment option also for other diseases associated with autism spectrum disorder.”
If I'm not mistaken Anavex owns the patent on one of the devices.